GON7

Across TCGA pan-cancer cohorts, GON7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GON7 data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GON7 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GON7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where GON7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.523	0.317	.006	25	view →
CCRCC	DFS	Median	III,IV	0.985	0.144	.008	9	view →
LUAD	DFS	Median	III,IV	0.620	0.867	.022	3	view →
HNSC	DFS	Median	III,IV	0.521	0.716	.041	3	view →
LSCC	DFS	Tertile	III,IV	0.867	0.471	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GON7–PDAC (DFS)

Open the PDAC breakdown →